Updates are available Correction dated 2022-09-13
Click to view Correction: https://doi.org/10.1038/s41586-022-05286-9
-
Authors
Gu, Xin https://orcid.org/0000-0002-3393-6927
Jouandin, Patrick https://orcid.org/0000-0002-8656-7694
Lalgudi, Pranav V.
Binari, Rich
Valenstein, Max L.
Reid, Michael A. https://orcid.org/0000-0001-6222-9538
Allen, Annamarie E.
Kamitaki, Nolan https://orcid.org/0000-0003-0614-0189
Locasale, Jason W. https://orcid.org/0000-0002-7766-3502
Perrimon, Norbert https://orcid.org/0000-0001-7542-472X
Sabatini, David M.
- License Information
-
More Information
Article History
Received: 4 November 2020
Accepted: 9 June 2022
First Online: 20 July 2022
Change Date: 13 September 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-022-05286-9
Competing interests
: D.M.S. is a shareholder of Navitor Pharmaceuticals, which is targeting for therapeutic benefit the amino-acid-sensing pathway upstream of mTORC1. J.W.L. advises Raphael Pharmaceuticals, Nanocare Technologies, Petri Biologics, and Restoration Foodworks. M.A.R. is currently employed by Amgen, which has interests in neurodegenerative diseases. These relationships have no overlap with this study. The other authors declare no competing interests.
